Prospective Clinicogenomic Program
The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.
Checked against the public recordLast updated Jan 17, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Other
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Genentech, Inc.
- Interventions being studied
- Other: Blood Draw
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Documented diagnosis of mNSCLC or ES-SCLC * Planned initiation of SOC systemic anti-cancer treatment * Front-Line Immunotherapy Cohort: Received front-line treatment of an immune blockade therapy including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibody on Protocol GX41563 Exclusion Criteria: \- Participant actively receiving investigational medicinal product(s) as part of an interventional trial at the time of signing informed consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Alabama OncologyBirmingham, Alabama
- Clearview Cancer InstituteHuntsville, Alabama
- Ironwood Cancer & Research CentersChandler, Arizona
- Yale UniversityNew Haven, Connecticut
- Florida Cancer Specialists; Department of OncologyFort Myers, Florida
- Florida Cancer Specialist, North RegionSt. Petersburg, Florida
- SCRI Florida Cancer Specialists PANTallahassee, Florida
- Florida Cancer SpecialistsWest Palm Beach, Florida
- University Cancer & Blood Center, LLC; ResearchAthens, Georgia
- Piedmont Cancer Institute, PCAtlanta, Georgia
- Fort Wayne Med Oncology & Hematology IncFort Wayne, Indiana
- Cancer & Hematology Centers of Western MichiganGrand Rapids, Michigan
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2024. Always confirm current availability with the study team.